




Mouse Anti-Human IgG Fc

Cat. No.	Format	Size
9040-01	Purified (UNLB)	0.5 mg
9040-02	Fluorescein (FITC)	0.5 mg
9040-04	Alkaline Phosphatase (AP)	1.0 mL
9040-05	Horseradish Peroxidase (HRP)	1.0 mL
9040-08	Biotin (BIOT)	0.5 mg
9040-09	R-phycoerythrin (PE)	0.1 mg
9040-30	Alexa Fluor® 488 (AF488)	0.1 mg
9040-31	Alexa Fluor® 647 (AF647)	0.1 mg
9040-32	Alexa Fluor® 555 (AF555)	0.1 mg



FLISA plate was coated with purified human IgG, IgM, and IgA. Immunoglobulins were detected with serially diluted Mouse Anti-Human IgG Fc-PE (SB Cat. No. 9040-09).

Overview

Clone	JDC-10
Isotype	Mouse IgG _{1κ}
Immunogen	Purified human IgG ₁ myeloma protein
Specificity	Human/Rhesus/Chimpanzee IgG Fc; Mr 150 kDa

Applications

ELISA – Quality tested ^{1-15,20}
 FLISA – Quality tested
 FC – Quality tested ^{18,19}
 IHC-PS – Reported in literature ¹⁶
 WB – Reported in literature ¹⁷
 Multiplex – Reported in literature ²⁰⁻²²

Working Dilutions

ELISA	AP conjugate	1:1,000 – 1:4,000
	HRP conjugate	1:2,000 – 1:8,000
	BIOT conjugate	1:5,000 – 1:10,000

FLISA	FITC, AF488, and AF555 conjugates	1:100 – 1:400
	PE and AF647 conjugates	≤ 1 µg/mL

Flow Cytometry	Purified (UNLB) antibody	≤ 1 µg/10 ⁶ cells
	FITC, BIOT, and AF488 conjugates	≤ 1 µg/10 ⁶ cells
	PE and AF647 conjugates	≤ 0.2 µg/10 ⁶ cells
	For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL	

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Alexa Fluor® 488 (AF488), Alexa Fluor® 555, and Alexa Fluor® 647 (AF647) conjugates are supplied as 0.1 mg in 0.2 mL of PBS/NaN₃. Store at 2-8°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Raux M, Finkielstejn L, Salmon-Céron D, Bouchez H, Excler JL, Dulouist E, et al. IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. *AIDS Res Hum Retroviruses*. 2000;16:583-94. (ELISA)
2. Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. *Clin Exp Immunol*. 2005;139:542-50. (ELISA)
3. Qian Y, Diaz LA, Ye J, Clarke SH. Dissecting the anti-desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients. *J Immunol*. 2007;178:5982-90. (ELISA)
4. Adekar SP, Jones RM, Elias MD, Al-Saleem FH, Root MJ, Simpson LL, et al. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. *J Immunol Methods*. 2008;333:156-66. (ELISA)
5. Xue L, Johnson R, Gorovits B. Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum. *AAPS J*. 2010;12:98-106. (ELISA)
6. Dreskin SC, Tripputi MT, Mustafa SS, Atkins D, Leo HL, et al. Peanut-allergic subjects and their peanut-tolerant siblings have large differences in peanut-specific IgG that are independent of HLA class II. *Clin Immunol*. 2010;137:366-73. (ELISA)
7. de Smit M, Westra J, Vissink A, Doornbos-van der Meer B, Brouwer E, van Winkelhoff AJ. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. *Arthritis Res Ther*. 2012;14:R222. (ELISA)
8. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. *J Infect Dis*. 2012;206:1836-43. (ELISA)
9. Christianson GJ, Sun VZ, Akilesh S, Pesavento E, Proetzl G, Roopenian DC. Monoclonal antibodies directed against human FcRn and their applications. *MAbs*. 2012;4:208-16. (ELISA)
10. Ravn P, Madhurantakam C, Kunze S, Matthews E, Priest E, O'Brien S, et al. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. *J Biol Chem*. 2013;288:19760-72. (ELISA)
11. Beaumont E, Patient R, Hourieux C, Dimier-Poisson I, Roingeard P. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. *Hepatology*. 2013;57:1303-13. (ELISA)
12. Dimitrov JD, Planchais C, Scheel T, Ohayon D, Mesnage S, Berek C, et al. A cryptic polyreactive antibody recognizes distinct clusters of HIV-1 glycoprotein 120 by an identical binding mechanism. *J Biol Chem*. 2014;289:17767-79. (ELISA)
13. Einarsdottir HK, Stapleton NM, Scherjon S, Andersen JT, Rispens T, van der Schoot CE, et al. On the perplexingly low rate of transport of IgG2 across the human placenta. *PLoS One*. 2014;9(9):e108319. (ELISA)
14. Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. *Clin Exp Immunol*. 2014;178:40-7. (ELISA)
15. Kapur R, Della Valle L, Verhagen OJ, Hipgrave Ederveen A, Ligthart P, de Haas M, et al. Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. *Transfusion*. 2014 Sep 19. doi: 10.1111/trf.12880. [Epub ahead of print]. (ELISA)
16. Pienaar IS, Lee CH, Elson JL, McGuinness L, Gentleman SM, Kalaria RN, et al. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease. *Neurobiol Dis*. 2015;74:392-405. (IHC-PS)
17. Lamoureux J, Aubin E, Lemieux R. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg?. *Int Immunol*. 2004;16:929-36. (WB)
18. Leyendeckers H, Odendahl M, Löhndorf A, Irsch J, Spangfort M, Miltenyi S, et al. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. *Eur J Immunol*. 1999;29:1406-17. (FC)
19. Cortez VS, Cervantes-Barragan L, Song C, Gilfillan S, McDonald KG, Tussiwand R, et al. CRTAM controls residency of gut CD4⁺CD8⁺ T cells in the steady state and maintenance of gut CD4⁺ Th17 during parasitic infection. *J Exp Med*. 2014;211:623-33. (FC)
20. Dasso J, Lee J, Bach H, Mage RG. A comparison of ELISA and flow microsphere-based assays for quantification of immunoglobulins. *J Immunol Methods*. 2002;263:23-33. (ELISA, Multiplex)
21. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. *J Virol*. 2008;82:12449-63. (Multiplex)
22. Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. *J Infect Dis*. 2014;210:99-110. (Multiplex)
23. Nonhuman Primate Reagent Resource (Rhesus & Chimpanzee Reactivity)

Alexa Fluor® 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

TB9040
30-Jul-20

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA **Mailing Address:** P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • **Fax:** 205.945.8768

Email: info@southernbiotech.com • **Website:** www.southernbiotech.com